What is HC Wainwright’s Forecast for LENZ Q2 Earnings?

LENZ Therapeutics, Inc. (NASDAQ:LENZ) – HC Wainwright issued their Q2 2025 earnings estimates for LENZ Therapeutics in a research note issued on Thursday, March 20th. HC Wainwright analyst M. Caufield anticipates that the company will post earnings per share of ($0.60) for the quarter. The consensus estimate for LENZ Therapeutics’ current full-year earnings is ($2.18) per share. HC Wainwright also issued estimates for LENZ Therapeutics’ Q4 2025 earnings at ($0.66) EPS, FY2025 earnings at ($2.52) EPS, FY2026 earnings at ($2.18) EPS, FY2027 earnings at ($1.02) EPS, FY2028 earnings at $0.18 EPS and FY2029 earnings at $1.45 EPS.

A number of other brokerages have also recently commented on LENZ. TD Cowen assumed coverage on LENZ Therapeutics in a report on Tuesday, March 18th. They set a “buy” rating and a $60.00 target price on the stock. Citigroup raised their target price on shares of LENZ Therapeutics from $44.00 to $47.00 and gave the stock a “buy” rating in a research report on Thursday. Seven research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $41.67.

LENZ Therapeutics Trading Up 0.7 %

Shares of NASDAQ LENZ opened at $26.49 on Monday. The stock has a market cap of $728.50 million, a price-to-earnings ratio of -5.55 and a beta of 0.58. The company’s 50-day moving average price is $24.15 and its 200 day moving average price is $27.08. LENZ Therapeutics has a 52 week low of $14.42 and a 52 week high of $38.93.

LENZ Therapeutics (NASDAQ:LENZ) last posted its earnings results on Wednesday, March 19th. The company reported ($0.46) EPS for the quarter, missing analysts’ consensus estimates of ($0.42) by ($0.04).

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of LENZ Therapeutics during the fourth quarter worth $29,000. KLP Kapitalforvaltning AS bought a new stake in LENZ Therapeutics during the fourth quarter worth approximately $46,000. Tower Research Capital LLC TRC raised its stake in shares of LENZ Therapeutics by 162.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company’s stock worth $54,000 after buying an additional 1,151 shares in the last quarter. Virtus ETF Advisers LLC acquired a new stake in LENZ Therapeutics in the 4th quarter valued at about $67,000. Finally, SG Americas Securities LLC raised its position in shares of LENZ Therapeutics by 20.7% during the fourth quarter. SG Americas Securities LLC now owns 5,458 shares of the company’s stock worth $158,000 after purchasing an additional 935 shares during the period. 54.32% of the stock is owned by institutional investors and hedge funds.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.